Zenas BioPharma (Nasdaq: ZBIO) is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative immunology-based therapies for patients in need. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas’ lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab’s mechanism of action and chronic dosing regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease.
Company Details
- Employees
- 141
- Address
- 1000 Winter St,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://zenasbio.com/
- Keywords
- Autoimmune Diseases and Immunology.
- HQ
- Waltham, MA
Zenas Biopharma Questions
Zenas Biopharma's website is https://zenasbio.com/
Zenas Biopharma's LinkedIn profile is https://www.linkedin.com/company/zenas-biopharma
Zenas Biopharma has
141 employees.
View email and phone details for 141
employees at Zenas Biopharma.
Zenas Biopharma's industry is
Biotechnology Research
Zenas Biopharma's top competitors are
Mbx Biosciences, Inc.,
Ionis Pharmaceuticals, Inc.,
Xencor,
Oruka Therapeutics,
Candid Therapeutics,
Bicara Therapeutics,
Viridian Therapeutics, Inc.,
Summit Therapeutics, Inc.,
Centessa Pharmaceuticals,
Bridgebio.
Zenas Biopharma's categories are Biotechnology Research
